MCP
CYTK icon

Mirador Capital Partners’s Cytokinetics CYTK Stock Holding History

Mirador Capital Partners’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$13.8M Buy
208,896
+6,526
+3% +$498K 1.6% 17
2026
Q2 		$17.2M Sell
202,370
-303
-0.1% -$21.8K 2.11% 11
2026
Q1 		$13.4M Buy
202,673
+4,115
+2% +$262K 1.89% 13
2025
Q4 		$12.6M Buy
198,558
+1,191
+0.6% +$74.1K 1.73% 14
2025
Q3 		$10.8M Buy
197,367
+53,020
+37% +$2.18M 1.54% 18
2025
Q2 		$4.77M Buy
144,347
+45,222
+46% +$1.57M 0.77% 33
2025
Q1 		$3.98M Buy
99,125
+33,489
+51% +$1.54M 0.7% 37
2024
Q4 		$3.09M Buy
65,636
+1,010
+2% +$52.5K 0.56% 41
2024
Q3 		$3.41M Buy
64,626
+1,483
+2% +$82.7K 0.61% 42
2024
Q2 		$3.42M Buy
63,143
+27,688
+78% +$1.67M 0.64% 40
2024
Q1 		$2.49M Sell
35,455
-13,497
-28% -$1.04M 0.47% 49
2023
Q4 		$4.09M Sell
48,952
-6,676
-12% -$242K 0.87% 30
2023
Q3 		$1.64M Buy
55,628
+1,890
+4% +$62.9K 0.37% 60
2023
Q2 		$1.75M Sell
53,738
-2,846
-5% -$105K 0.42% 61
2023
Q1 		$1.99M Sell
56,584
-2,148
-4% -$87.6K 0.47% 52
2022
Q4 		$2.69M Sell
58,732
-69,753
-54% -$3M 0.64% 39
2022
Q3 		$6.22M Sell
128,485
-35,098
-21% -$1.69M 1.5% 17
2022
Q2 		$6.43M Buy
163,583
+4,085
+3% +$164K 1.52% 18
2022
Q1 		$5.87M Buy
159,498
+6,879
+5% +$244K 1.19% 21
2021
Q4 		$6.96M Sell
152,619
-10,857
-7% -$419K 1.46% 19
2021
Q3 		$5.84M Buy
163,476
+4,977
+3% +$147K 1.33% 21
2021
Q2 		$3.14M Buy
158,499
+9,415
+6% +$221K 0.71% 46
2021
Q1 		$3.47M Sell
149,084
-3,311
-2% -$70.7K 0.89% 37
2020
Q4 		$3.17M Buy
152,395
+40,271
+36% +$736K 0.87% 41
2020
Q3 		$2.43M Buy
112,124
+16,017
+17% +$375K 0.76% 44
2020
Q2 		$2.27M Sell
96,107
-1,247
-1% -$23.4K 0.85% 39
2020
Q1 		$1.62M Sell
97,354
-5,122
-5% -$65.3K 0.68% 46
2019
Q4 		$1.09M Buy
+102,476
New +$1.05M 0.44% 64

Other funds holding CYTK

Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
VC
Veracity Capital Atlanta, Georgia $372M AUM 32.95% 1-Year Est. Return
GIA
Gateway Investment Advisers Cincinnati, Ohio $11B AUM 34.31% 1-Year Est. Return
BCG
Breakwater Capital Group Paramus, New Jersey $844M AUM 15.36% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
EWP
Elevation Wealth Partners Santa Rosa, California $356M AUM 17.04% 1-Year Est. Return
TC
Trust Company Manhattan, Kansas $1.15B AUM 7.83% 1-Year Est. Return

Mirador Capital Partners's CYTK Position: Q3 2026 in Review

Mirador Capital Partners increased its Cytokinetics (CYTK) stake by 3.2% in Q3 2026, buying an estimated $498K and bringing the position to 208,896 shares worth $13.8M. The position accounts for 1.6% of the portfolio, ranked #17.

Mirador Capital Partners first reported a position in CYTK in Q4 2019 and has held it in 28 quarters since. The position peaked at $17.2M in Q2 2026. 13 funds tracked by Wall St. Rank hold CYTK as of Q3 2026.

  • Mirador Capital Partners held 208,896 shares of Cytokinetics worth $13.8M as of Q3 2026.
  • Mirador Capital Partners bought 6,526 Cytokinetics shares in Q3 2026, an estimated $498K.
  • Cytokinetics made up 1.6% of Mirador Capital Partners's portfolio in Q3 2026, its #17 holding.
  • Mirador Capital Partners first reported a position in Cytokinetics in Q4 2019 and has held it in 28 quarters since.
  • Mirador Capital Partners's Cytokinetics position peaked at $17.2M in Q2 2026.
  • 13 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2026.

Based on Mirador Capital Partners's 13F filing for Q3 2026, filed 9 Oct 2026.